Avecho Biotechnology Limited (ASX:AVE)
0.0100
0.00 (0.00%)
Jan 30, 2026, 2:42 PM AEST
Avecho Biotechnology Revenue
Avecho Biotechnology had revenue of 560.07K AUD in the half year ending June 30, 2025, with 25.45% growth. This brings the company's revenue in the last twelve months to 1.38M, up 306.88% year-over-year. In the year 2024, Avecho Biotechnology had annual revenue of 1.13M with 139.19% growth.
Revenue (ttm)
1.38M
Revenue Growth
+306.88%
P/S Ratio
26.61
Revenue / Employee
92.04K
Employees
15
Market Cap
36.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.13M | 659.12K | 139.19% |
| Dec 31, 2023 | 473.55K | -655.71K | -58.07% |
| Dec 31, 2022 | 1.13M | 335.66K | 42.30% |
| Dec 31, 2021 | 793.60K | 408.97K | 106.33% |
| Dec 31, 2020 | 384.63K | -3.85M | -90.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 12.51M |
| Amplia Therapeutics | 5.01M |
| Argenica Therapeutics | 3.21M |
| Noxopharm | 2.82M |
| Tissue Repair | 2.63M |
| Neurotech International | 2.44M |
| Cynata Therapeutics | 1.89M |
| Entropy Neurodynamics | 1.58M |